AbbVie (ABBV) is out with data from SAPPHIRE-I (that's the first of six 3D Phase 3 GT1 HCV trials).
SVR12 rates: 95% in GT1a and 98% in GT1b.
Regulatory submissions expected in Q2 of next year. (PR)
Worth watching on the news: Enanta (ENTA), which discovered one of the regimen's components (ABT-450) as part of an ongoing collaboration with ABBV.